With extensive expertise in cell biology, Creative Bioarray combines patient-derived iPSC with gene-editing technologies such as CRISPR-Cas9 to develop effective therapeutic models, providing researchers with new tools to explore the pathophysiology of Alzheimer's disease (AD) and find the best pharmacological options for patients. Our specialized scientific solutions will accelerate our clients' research progress in the field of cell reprogramming.
iPSC for AD Modeling
AD is a severe neurodegenerative disorder characterized pathologically by extracellular Aβ plaques and aggregation of hyperphosphorylated tau proteins in neurogenic fiber tangles, which eventually leads to the serious loss of cognitive function and behavioral ability. Animal models of AD have been shown to fail to accurately represent the pathology of human AD, and these models often exhibit only a few pathological features and lack important components, such as extensive neuronal loss and the accumulation of neurofibrillary tangles (NFTs). This can be attributed to the fact that rodent tau proteins may be difficult to form in aggregates due to sequence and structural differences, and the short lifespan of mice makes it difficult to accumulate events that would take decades in humans.
Many research teams have developed iPSC-based 2D models, which reveal to some extent some of the key pathophysiological mechanisms of AD, but they cannot recapitulate all disease features of AD. The development of sophisticated 3D models in vitro overcomes the limitations of 2D culture and provides a valuable potential approach to study adult AD. In conclusion, the application of reprogramming techniques to the development of bioengineered human cell-based AD models offers the potential to elucidate and validate the pathogenesis of AD.
Fig.1 Alzheimer's Disease model. (Valadez-Barba, 2020)
Our Solutions
Creative Bioarray has developed several iPSC-based modeling strategies for AD, and our professional technical support and solutions will help customers to effectively explore the disease mechanisms of AD.
- We have differentiated patient-derived iPSC into multiple brain cell types for 3D in vitro AD modeling. This 3D neurosphere model based on iPSCs from AD patients provides the basis for more accurate drug screening methods and facilitates subsequent research of individual phenotypic variation, allowing for a personalized approach to treating AD.
- We have developed a triple-culture AD model including astrocytes, neurons, and microglia to simulate blood flow by using a microfluidic platform to more accurately present the disease process in AD. The experimental system replicates key features of AD, such as the accumulation of hyperphosphorylated tau proteins, and neuroinflammation.
- We develop complex 3D models of neuronal cell cultures in microfluidic systems by adding brain endothelial cells with blood-brain barrier (BBB)-like phenotypes to help our clients unravel the physiological and pathological mechanisms of BBB dysfunction in AD.
Advantages
- Flexible solutions for different customer needs
- Extensive experience and advanced technologies
- One-stop service
Creative Bioarray relies on a first-class experimental platform and a professional research team to provide AD disease modeling solutions to our clients. We have successfully differentiated iPSCs induced from somatic cells into specific cell types to model a variety of known diseases worldwide. please contact us directly if you need our services.
Reference
- Valadez-Barba, V.; et al. iPSC for modeling neurodegenerative disorders. Regenerative Therapy. 2020, 15: 332-339.